Global Bio-chem Technology Group Company Limited provided consolidated earnings guidance for the year ending December 31, 2013. Based on the preliminary review of the draft unaudited consolidated management accounts of the group for the eleven months ended 30 November 2013, the board of directors of the company informed that the results of the company for the year ending 31 December 2013 is expected to record a further increase of loss as compared with that for the year ended 31 December 2012. It was mainly attributable to the decline in the price and demand of the group's products which in particular, the sale of the group's lysine products was affected by the recent emerge of the new bird flu strain and the possible provision for inventories of the group.